Strides Pharma Science Limited (Star) (NSE: STAR, BSE: 532531) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹9,212 Cr, it ranks #619 by market cap among the 6,197 Indian listed companies on FinBizNet, and #12 of 63 in Pharmaceuticals. At ₹1,008.70 (as of 16 Nov 2026), the share price is 20.0% below its 52-week high of ₹1,260.90 and 31.2% above its 52-week low of ₹768.65. The share price is up 7.0% over one year and up 2.6% over three months.
| Current Price | ₹1,008.70 |
|---|---|
| Market Cap | ₹9,212 Cr |
| NSE Symbol | STAR |
| BSE Code | 532531 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 16.8 |
| Return on Equity | 20.03% |
| Return on Assets | 6.26% |
| 52-Week Range | ₹768.65 – ₹1,260.90 |
| 1-Year Price Change | +7.0% |
| 3-Month Price Change | +2.6% |
| Beta (1Y) | 0.43 |
| Dividend Yield | 0.49% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.strides.com |
| Revenue | ₹1,430 Cr |
|---|---|
| Net Profit | ₹134 Cr |
| Net Margin | 9.4% |
| EPS (Basic) | ₹14.19 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr in Q2 FY27, up 17.1% from ₹1,221 Cr in Q2 FY26 and up 13.0% from ₹1,265 Cr in Q1 FY27. It posted a net profit of ₹134 Cr for the quarter, against a net profit of ₹132 Cr in Q2 FY26 (up 2.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,120 Cr (Q1 FY26) to ₹1,430 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,430 Cr | ₹134 Cr | 9.4% |
| Q1 FY27 | ₹1,265 Cr | ₹165 Cr | 13.1% |
| Q4 FY26 | ₹1,323 Cr | ₹129 Cr | 9.8% |
| Q3 FY26 | ₹1,195 Cr | ₹208 Cr | 17.4% |
| Q2 FY26 | ₹1,221 Cr | ₹132 Cr | 10.8% |
| Q1 FY26 | ₹1,120 Cr | ₹106 Cr | 9.4% |
| Q4 FY25 | ₹1,190 Cr | ₹86 Cr | 7.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 29.00% of Strides Pharma Science Limited (Star)'s shares as of Sept 2026, against 27.86% in Sept 2025 (+1.14 percentage points). Delivery averaged 49.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-This segment develops and manufactures pharmaceutical products. 2. Bio-Pharmaceutical Business-This segment engages in bio-pharmaceutical business. 3. Pharmaceutical Business-This segment develops and manufactures pharmaceutical products. 4. Biotech Business-This segment is involved in biotech business.
1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Strides Pharma Science Limited (Star) | ₹9,212 Cr | 16.8 | 20.03% | ₹1,430 Cr | +7.0% |
Listed by market capitalisation. Ratios are shown for context only.
Strides Pharma Science Limited (Star) is trading at ₹1,008.70, with a market capitalisation of ₹9,212 Cr.
Strides Pharma Science Limited (Star) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Strides Pharma Science Limited (Star) has a P/E of 16.8 and a return on equity of 20.03%.
Strides Pharma Science Limited (Star) is listed on the NSE under the symbol STAR and on the BSE under the scrip code 532531.
Strides Pharma Science Limited (Star)'s share price is up 7.0% over one year and up 2.6% over three months. Its 52-week range is ₹768.65 to ₹1,260.90.
In Q2 FY27, Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr and net profit of ₹134 Cr, with basic EPS of ₹14.19 (consolidated, parsed from the company's exchange filing).
Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr in Q2 FY27, up 17.1% from ₹1,221 Cr in Q2 FY26 and up 13.0% from ₹1,265 Cr in Q1 FY27.
Promoters held 29.00% of Strides Pharma Science Limited (Star)'s shares as of Sept 2026, against 27.86% in Sept 2025 (+1.14 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.